A clinical comparison of molindone hydrochloride with trifluoperazine in psychotic outpatients. High dose trifluoperazine therapy in chronic schizophrenia. Controlled trial of sulpiride in chronic schizophrenic patients. A twelve month comparison of penfluridol and trifluoperazine in chronic schizophrenic outpatients. Differential drug effects of two phenothiazines. (A controlled comparison of thioridazine and trifluoperazine in chronic schizophrenics). A double-blind comparative trial of loxapine and trifluoperazine in acute and chronic schizophrenic patients. A standard- (trifluoperazine) controlled clinical study with pimozide in the maintenance treatment of schizophrenic patients, II. A comparative study of fluphenazine enanthate and trifluoperazine in chronic schizophrenic patients. Pimozide: a comparative study in the treatment of chronic schizophrenic patients. A comparative study of molindone and trifluoperazine. A comparison of two butyrophenones with trifluoperazine. Acute paranoid schizophrenia. (Treatment with chlorpromazine, trifluoperazine and placebo). Thiothixene: a controlled evaluation of the intramuscular antipsychotic preparation. A double-blind comparison of pimozide vs. trifluoperazine in schizophrenic outpatients. A double-blind study of SKF 14336 vs. trifluoperazine in schizophrenic patients. A double-blind comparison of loxapine succinate and trifluoperazine in newly admitted schizophrenic patients. A double-blind comparison of once-a-day pimozide, trifluoperazine, and placebo in the maintenance care of chronic schizophrenic outpatients. A double-blind comparison of the acridane derivative, clomacran phosphate and trifluoperazine in schizophrenia. WITHDRAWAL OF LONG-TERM PHENOTHIAZINES FROM CHRONICALLY HOSPITALIZED PSYCHIATRIC PATIENTS. Double blind comparison of thiothixene and trifluoperazine in acute schizophrenia. Loxapine: a controlled evaluation in chronic schizophrenic patients. GP-45795: a controlled evaluation in chronic schizophrenic patients. A double-blind comparison of molindone and trifluoperazine in the treatment of acute schizophrenia. Chlorpromazine, trifluoperazine and placebo with long-term mental hospital patients. [Comparative study of clothiapine and trifluoperazine in acute episodes of paranoid schizophrenia]. A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: a double-blind controlled study on the treatment of chronic, hospitalized, schizophrenic patients. Efficacy of trifluoperazine on withdrawal in chronic schizophrenia. Centbutindole vs trifluoperazine: a double-blind controlled clinical study in acute schizophrenia. A controlled clinical trial of trifluperidol on a group of chronic schizophrenic patients. Haloperidol--new addition to the drug treatment of schizophrenia. Comparison of the clinical and electroencephalographical effects of molindone and trifluoperazine in acute schizophrenic patients. Management of hostile, suspicious patients. Trifluoperazine versus haloperidol. A comparison of fluspirilene and trifluoperazine in the treatment of acute schizophrenic psychosis. Trifluperidol and trifluoperazine in acute schizophrenic patients. A double-blind comparison of trifluperidol and trifluoperazine in acute schizophrenic patients. Haloperidol in controlling the symptoms of acute psychoses. II. A double-blind evaluation of haloperidol and trifluoperazine. Loxapine in newly admitted chronic schizophrenic patients. A standard- (trifluoperazine) controlled clinical study with pimozide in the maintenance treatment of schizophrenic patients, I. Comparative effects of intramuscular thiothixene and trifluoperazine in psychotic patients. A controlled study of SK&F 14336 in acute schizophrenia. Thiothixene versus trifluoperazine in newly-admitted schizophrenic patients. A CONTROLLED EVALUATION OF BUTAPERAZINE IN CHRONIC SCHIZOPHRENIC PATIENTS. A COMPARISON OF SKF-7261 AND TRIFLUOPERAZINE (STELAZINE) IN THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
nan nan In a double-blind comparative trial of sulpiride (600-1,800 mg/day) and trifluoperazine (15-45 mg/day) in 38 chronic schizophrenic patients, ratings of therapeutic results and unwanted effects were made at two-weekly interviews during the six weeks treatment period. The results show that sulpiride has neuroleptic properties and a spectrum of therapeutic activity similar to that of trifluoperazine. There was an association between plasma sulpiride levels and therapeutic response after four weeks' treatment. This investigation is a 52-week double-blind study comparing the efficacy and safety of penfluridol and trifluoperazine in 25 chronic schizophrenic outpatients. Penfluridol was administered once weekly and trifluoperazine daily. Measurements were made at baseline, various fixed intervals during the study period and termination. The data reveals that both agents were similarly effective in maintaining control of the symptoms of chronic schizophrenic patients at a level commensurate with or better than that provided by their previous medication. Besides being effective, medications were also well tolerated. The side effects were characteristic of marketed neuroleptics. Akathisia was more common with penfluridol but readily controlled with anti-parkinsonian medication. Other side effects were similar in severity and occurrence between study-drug groups. Both agents had low autonomic liability, and neither agent was depressogenic. nan A double-blind comparative trial of loxapine and trifluoperazine was carried out in 57 acute and chronic schizophrenic patients. In both groups of patients loxapine proved to be equivalent in its effects to trifluoperazine and there were suggestions it might be rather more effective in chronic patients. Side-effects were similar with the two drugs but anticholinergic effects, excitement, dizziness and faintness occurred rather more commonly with loxapine. Laboratory tests, urine analysis, cardiovascular and ophthalmological investigations showed no significant abnormalities. nan nan nan nan nan nan nan nan nan A study was conducted evaluating the efficacy of loxapine succinate in newly admitted schizophrenic patients through a four-week double-blind comparison with trifluoperazine. Twenty-four patients received between 40 and 80 mg loxapine succinate daily and 19 patients received between 20 and 50 mg trifluoperazine daily. The two groups showed comparable significant improvement on the BPRS and CGI. The discharge and termination rates of the two groups were not significantly different and the incidence and severity of side effects, most frequently extrapyramidal signs, were similar in both groups. Loxapine succinate was judged to be an effective treatment for newly admitted schizophrenic patients. nan nan nan nan nan nan nan nan nan nan nan Twenty-nine acute schizophrenic patients were treated under double-blind conditions for six weeks with either centbutindole in a dose range of 3 mg/day to 4.5 mg/day or trifluoperazine in the dose range of 15 mg/day to 22.5 mg/day. Both drugs produced a significant improvement in initial psychopathology. No significant differences were demonstrated between the two treatment conditions. nan nan nan In a population of hostile suspicious patients mostly fitting into the paranoid schizophrenic category, haloperidol and trifluoperazine when compared in double-blind fashion were equal in global clinical ratings. Haloperidol showed significantly more improvement on the Brief Psychiatric Rating Scale and on the Global Paranoia rating. On the Global Hostility rating and in speed of onset of activity, the effects of the two drugs were not significantly different. In a small sub-sample of extremely uncooperative patients haloperidol showed marked effects, but trifluoperazine showed only minimal or moderate effects. nan nan nan nan The standard drug Stelazine (STEL), at a dose of 50 mg/day, exhibited therapeutic activity significantly different from placebo (PL) activity on several variables, most notably BPRS, attesting to the sensitivity of the experiment. On the other hand, the investigational drug, loxapine (LOX), in doses of 100 mg/day for four weeks, could be differentiated from PL as treatment in the described population on only one variable (NGI-Imp.) and one item of the BPRS. On several variables, positive trends were noted, but the differences from PL did not attain the critical values necessary for statistical significance at P smaller than 0.05. One might speculate that the relatively short duration of treatment in this study might account for the difference between these disappointing results and the more gratifying results of a previous loxapine study in chronic long-term institutionalized schizophrenics with the same oral dose. nan nan nan nan nan nan
Although there are shortcomings and gaps in the data, there appears to be enough consistency over different outcomes and periods to confirm that trifluoperazine is an antipsychotic of similar efficacy to other commonly used neuroleptics for people with schizophrenia. Its adverse events profile is similar to that of other drugs. It has been claimed that trifluoperazine is effective at low doses for patients with schizophrenia but this does not appear to be based on good quality trial based evidence.